Gal-ARV-771
Product Specifications
UNSPSC Description
Gal-ARV-771, PROTAC prodrug, is a gal modified ARV-771 (HY-100972). Gal-ARV-771 can be activated in SA-β-Gal-expressed cancer senescent cells to release ARV-771. Gal-ARV-771 induces selective degradation of BRD4 protein by the ubiquitin-proteasome pathway in senescent cells. Gal-ARV-771 promotes apoptosis of senescent cancer cells[1].
Target Antigen
Apoptosis; Epigenetic Reader Domain; PROTACs
Type
Reference compound
Related Pathways
Apoptosis;Epigenetics;PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/gal-arv-771.html
Solubility
10 mM in DMSO
Smiles
O=C(N[C@@H](C)C1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)OC(OCC4=CC=C(O[C@@H]([C@@H]5OC(C)=O)O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@@H]5OC(C)=O)C=C4)=O)C([C@H](C(C)(C)C)NC(COCCCOCCNC(C[C@@H]6N=C(C7=C(N8C(C)=NN=C68)SC(C)=C7C)C9=CC=C(C=C9)Cl)=O)=O)=O
Molecular Weight
1467.06
References & Citations
[1]Chang M, et al. Selective Elimination of Senescent Cancer Cells by Galacto-Modified PROTACs. J Med Chem. 2024 May 9;67(9):7301-7311.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-158331/Gal-ARV-771-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-158331/
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
